Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Xencor (XNCR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (VKTX – Research Report), Xencor (XNCR – Research Report) and Veeva Systems (VEEV – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Viking Therapeutics (VKTX)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics. The company’s shares closed last Wednesday at $32.14, close to its 52-week low of $24.41.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $93.00 average price target, a 189.5% upside from current levels. In a report issued on February 25, BTIG also maintained a Buy rating on the stock with a $125.00 price target.
See the top stocks recommended by analysts >>
Xencor (XNCR)
Truist Financial analyst Gregory Renza maintained a Buy rating on Xencor today. The company’s shares closed last Wednesday at $12.74, close to its 52-week low of $10.90.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
Currently, the analyst consensus on Xencor is a Strong Buy with an average price target of $26.39, representing an 115.4% upside. In a report issued on February 25, TD Cowen also maintained a Buy rating on the stock.
Veeva Systems (VEEV)
Oppenheimer analyst Kenneth Wong reiterated a Buy rating on Veeva Systems today and set a price target of $275.00. The company’s shares closed last Wednesday at $188.48.
According to TipRanks.com, Wong is a 4-star analyst with an average return of
Currently, the analyst consensus on Veeva Systems is a Moderate Buy with an average price target of $266.37, which is a 42.8% upside from current levels. In a report issued on February 19, TipRanks – xAI also upgraded the stock to Buy with a $200.00 price target.
